Breakthrough Cancer Therapy Enters Human Trials: What Investors Need to Know

Oxford, Monday, 22 June 2026.
Oxford BioTherapeutics and Boehringer Ingelheim have dosed the first patients with BI 3820768, their third joint cancer therapy to reach clinical trials. This milestone, coupled with obrixtamig advancing to Phase 3, signals a leap in antibody-based oncology treatments. With DLL3 present in 80-85% of small cell lung cancers, this therapy could redefine treatment for aggressive cancers. Investors take note: this collaboration is accelerating drug development and expanding therapeutic options.